APLT Applied Therapeutics Inc.
NewsSee all news
-
Applied Therapeutics to Present Preclinical Data Highlighting AT-001 for the Treatment of Diabetic Cardiomyopathy at the 55th Annual Meeting of the European Association for the Study of Diabetes (EASD)
NEW YORK, Sept. 17, 2019 (GLOBE NEWSWIRE) -- Applied Therapeutics Inc. (NASDAQ:APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in
-
Applied Therapeutics to Present Data Highlighting AT-001 for the Treatment of Diabetic Cardiomyopathy at the Heart Failure Society of America (HFSA) 23rd Annual Scientific Meeting
NEW YORK, Sept. 13, 2019 (GLOBE NEWSWIRE) -- Applied Therapeutics Inc. (NASDAQ:APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in
Drug Information
Drug catalyst information is displayed when you hover over / tap on the stage bar graph.
Latest News
-
Applied Therapeutics to Present Preclinical Data Highlighting AT-001 for the Treatment of Diabetic Cardiomyopathy at the 55th Annual Meeting of the European Association for the Study of Diabetes (EASD)
NEW YORK, Sept. 17, 2019 (GLOBE NEWSWIRE) -- Applied Therapeutics Inc. (NASDAQ:APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in
-
Applied Therapeutics to Present Data Highlighting AT-001 for the Treatment of Diabetic Cardiomyopathy at the Heart Failure Society of America (HFSA) 23rd Annual Scientific Meeting
NEW YORK, Sept. 13, 2019 (GLOBE NEWSWIRE) -- Applied Therapeutics Inc. (NASDAQ:APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in